Abstract
Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Keywords: Amyloid, Proteases, Alzheimers Disease
Current Pharmaceutical Design
Title: Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Volume: 8 Issue: 28
Author(s): Frauke Schimmoller, Jeffrey N. Higaki and Barbara Cordell
Affiliation:
Keywords: Amyloid, Proteases, Alzheimers Disease
Abstract: Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Export Options
About this article
Cite this article as:
Schimmoller Frauke, Higaki N. Jeffrey and Cordell Barbara, Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (28) . https://dx.doi.org/10.2174/1381612023392658
DOI https://dx.doi.org/10.2174/1381612023392658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Carotid and Vertebral Arterial Variations in Alzheimer's Disease
Current Alzheimer Research Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran
Infectious Disorders - Drug Targets Lower Serum Indirect Bilirubin Levels are Inversely Related to Carotid Intima-Media Thickness Progression
Current Neurovascular Research Polymorphism rs9939609 of Fat Mass and Obesity-associated Gene Correlation with Leptin Level of Obese Women Suffered from Type 2 Diabetes
Current Diabetes Reviews Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology)
Current Pharmacogenomics and Personalized Medicine A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications
Current Medicinal Chemistry Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Letters in Drug Design & Discovery Mapping and Annotating Obesity-Related Genes in Pig And Human Genomes
Protein & Peptide Letters The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology Preface:
Current Diabetes Reviews Safety and Efficacy of Intra-arterial Tirofiban Injection During Mechanical Thrombectomy for Large Artery Occlusion
Current Neurovascular Research Metabolomics Applications in Precision Medicine: An Oncological Perspective
Current Topics in Medicinal Chemistry Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research